S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:ZYNE

Zynerba Pharmaceuticals (ZYNE) Stock Forecast, Price & News

$1.34
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.32
$1.34
50-Day Range
$0.33
$1.39
52-Week Range
$0.25
$1.40
Volume
603,578 shs
Average Volume
662,366 shs
Market Capitalization
$72.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.11

Zynerba Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
17.2% Downside
$1.11 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$64,033 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.84) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.16 out of 5 stars

Medical Sector

942nd out of 963 stocks

Pharmaceutical Preparations Industry

450th out of 458 stocks


ZYNE stock logo

About Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

ZYNE Price History

ZYNE Stock News Headlines

ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing
In just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing
In just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
See More Headlines
Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Company Calendar

Last Earnings
8/14/2023
Today
9/24/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZYNE
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.11
High Stock Price Forecast
$1.11
Low Stock Price Forecast
$1.11
Forecasted Upside/Downside
-17.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-35,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.01 per share

Miscellaneous

Free Float
46,905,000
Market Cap
$72.28 million
Optionable
Optionable
Beta
1.33
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Armando Anido MBA (Age 65)
    Chairman & CEO
    Comp: $934.53k
  • Ms. Terri B. Sebree (Age 65)
    Pres
    Comp: $729.15k
  • Mr. James E. Fickenscher (Age 59)
    CFO & VP of Corp. Devel. (Leave of Absence)
    Comp: $607.62k
  • Mr. Kenneth T. Jones (Age 59)
    VP, Corp. Controller & Interim CFO
  • Mr. Albert P. Parker II (Age 57)
    Chief Legal Officer & Corp. Sec.
  • Mr. Joseph Apostolico
    VP of HR













ZYNE Stock - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares.
View ZYNE analyst ratings
or view top-rated stocks.

What is Zynerba Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 12-month target prices for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $1.11 to $1.11. On average, they expect the company's share price to reach $1.11 in the next year. This suggests that the stock has a possible downside of 17.2%.
View analysts price targets for ZYNE
or view top-rated stocks among Wall Street analysts.

How have ZYNE shares performed in 2023?

Zynerba Pharmaceuticals' stock was trading at $0.53 at the start of the year. Since then, ZYNE shares have increased by 152.8% and is now trading at $1.34.
View the best growth stocks for 2023 here
.

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 240,600 shares, an increase of 286.8% from the August 15th total of 62,200 shares. Based on an average daily volume of 769,300 shares, the short-interest ratio is currently 0.3 days.
View Zynerba Pharmaceuticals' Short Interest
.

When is Zynerba Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ZYNE earnings forecast
.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01.

What ETF holds Zynerba Pharmaceuticals' stock ?

Amplify Seymour Cannabis ETF holds 220,858 shares of ZYNE stock, representing 0.30% of its portfolio.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.38%), Renaissance Technologies LLC (1.29%), Bernardo Wealth Planning LLC (0.15%), Wells Fargo & Company MN (0.14%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher, Kenneth T Jones, Pamela Stephenson and Terri B Sebree.
View institutional ownership trends
.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $1.34.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $72.28 million. The company earns $-35,040,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com.

This page (NASDAQ:ZYNE) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -